Expert Commentary by Professor Yilong Wu: The Evolution of Molecularly Driven Precision Stratification and Comprehensive Treatment Strategies in Lung Cancer
In driver gene-positive non-small cell lung cancer (NSCLC), mesenchymal-epithelial transition factor (MET) abnormalities represent an important bypass resistance mechanism in patients with epidermal growth factor receptor (EGFR) mutations. Primary MET overexpression is also often associated with poor efficacy of EGFR tyrosine kinase inhibitor (TKI) monotherapy. How to overcome resistance through precision treatment and achieve more refined patient stratification in the first-line setting remain pressing challenges for the global lung cancer community.









